Akari Therapeutics ADR (AKTX)

$0.93 +0.02 (2.05%)
Market Cap 24.10M
Revenue (ttm) 0.00
Net Income (ttm) -10.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,000
Avg Vol 42,858
Day's Range N/A - N/A
Shares Out 26.59M
Stochastic %K 29%
Beta 0.89
Analysts Strong Sell
Price Target $4.00

Latest News on AKTX

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Mar 3, 2025, 9:00 AM EST - 5 days ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 17 days ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Feb 3, 2025, 8:00 AM EST - 4 weeks ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Key Leadership Appointments

Dec 18, 2024, 8:51 AM EST - 2 months ago

Akari Therapeutics Announces Key Leadership Appointments

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Dec 16, 2024, 9:05 AM EST - 2 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 14, 2024, 4:15 PM EST - 4 months ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Nov 8, 2024, 8:00 AM EST - 4 months ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 4:15 PM EDT - 7 months ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Aug 19, 2024, 8:00 AM EDT - 7 months ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 16, 2024, 8:00 AM EDT - 10 months ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:01 AM EDT - 11 months ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

May 1, 2024, 8:00 AM EDT - 11 months ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 15, 2024, 8:00 AM EDT - 11 months ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 14, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present at Biotech Showcase 2024

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Dec 1, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 16, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari Therapeutics to Present at Emerging Growth Conference

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present at Emerging Growth Conference

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 18, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 15, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Plc Announces ADS Ratio Change

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Jul 27, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Jul 19, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Jul 13, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Jul 11, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Jul 6, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

Jul 5, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

May 16, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

May 1, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Apr 25, 2023, 4:15 PM EDT - 2 years ago

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Apr 14, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

Mar 30, 2023, 9:09 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

Mar 29, 2023, 8:00 AM EDT - 2 years ago

Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Feb 21, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Feb 15, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

Feb 13, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

Akari Therapeutics to Present at Biotech Showcase™ 2023

Jan 4, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present at Biotech Showcase™ 2023

Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

Dec 1, 2022, 8:00 AM EST - 2 years ago

Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

Nov 22, 2022, 8:00 AM EST - 2 years ago

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

Nov 10, 2022, 8:00 AM EST - 2 years ago

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA